Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

Fig. 3

Survival outcomes based on changes in peripheral immune cell populations in the PALOMA-2 validation cohort. A, B Progression-free survival according to the dNLR ratio (cut-off = 1.61) at baseline in letrozole plus placebo-treated (N = 209) (A) or letrozole plus palbociclib-treated (N = 410) (B) patients. C, D Progression-free survival according to the dNLR ratio (cut-off = 1.04) after treatment (cycle 2 day 1) in letrozole plus palbociclib-treated patients (C) and in letrozole plus palbociclib-treated patients with higher baseline dNLR ratios (cut-off = 1.61) (D). E Forest plot of the dNLR ratio on progression-free survival in the validation cohort treated with letrozole plus palbociclib. CI, confidence interval; dNLR, derived neutrophil-to-lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; PFS, progression-free survival

Back to article page